1. Which statement most precisely describes the molecular mechanism by which chloroquine exerts its antimalarial effect within the intraerythrocytic parasite?
A) It inhibits parasite dihydrofolate reductase, blocking pyrimidine synthesis required for DNA replication
B) It binds free heme (ferriprotoporphyrin IX) and inhibits its polymerization into insoluble hemozoin (beta-hematin), so cytotoxic free heme accumulates in the digestive vacuole
C) It cleaves into free radicals upon contact with heme iron, alkylating parasite proteins and lipids
D) It inhibits the parasite cytochrome bc1 complex, collapsing the mitochondrial membrane potential
E) It binds the parasite 70S ribosome and arrests apicoplast protein synthesis
ANSWER: B
Rationale:
Chloroquine accumulates in the acidic digestive vacuole, where it binds free heme (ferriprotoporphyrin IX) released during hemoglobin catabolism and inhibits the parasite's polymerization of that heme into inert, insoluble hemozoin (beta-hematin). The resulting accumulation of cytotoxic free heme and chloroquine-heme complexes disrupts the vacuolar membrane and kills the parasite. This is the precise mechanism.
Option A: Option A describes the antifolate pyrimethamine/proguanil mechanism, not chloroquine.
Option C: Option C describes artemisinin radical generation, not chloroquine.
Option D: Option D describes atovaquone (cytochrome bc1 inhibition), not chloroquine.
Option E: Option E describes the antibiotic antimalarials acting on the apicoplast ribosome (for example doxycycline, clindamycin), not chloroquine.
2. Quinine and quinidine are stereoisomers used historically in malaria. Which statement correctly distinguishes them?
A) Quinine is the dextrorotatory isomer and is the more potent cardiac antiarrhythmic of the two
B) Quinine and quinidine are identical molecules differing only in trade name
C) Quinidine is a synthetic 8-aminoquinoline with no antimalarial activity
D) Quinidine is the dextrorotatory stereoisomer of quinine and is the more potent cardiac (class IA) antiarrhythmic, while quinine is the preferred antimalarial alkaloid
E) Quinine is gametocytocidal and used solely for transmission blocking, whereas quinidine treats blood-stage disease
ANSWER: D
Rationale:
Quinidine is the dextrorotatory (right-rotating) stereoisomer of quinine. It is slightly more potent as an antimalarial but substantially more potent as a class IA cardiac antiarrhythmic, which is why quinidine was historically used both for arrhythmias and as the parenteral antimalarial in settings where intravenous quinine was unavailable. This is correct.
Option A: Option A is incorrect because it inverts the configuration: quinine is levorotatory, not dextrorotatory, and is not the more potent antiarrhythmic.
Option B: Option B is incorrect because stereoisomers are distinct molecules with different pharmacologic potencies, not mere trade-name variants.
Option C: Option C is incorrect because quinidine is a cinchona alkaloid stereoisomer with genuine antimalarial activity, not a synthetic 8-aminoquinoline.
Option E: Option E is incorrect because gametocytocidal transmission-blocking activity is the property of primaquine, not quinine, and both quinine and quinidine act on blood-stage parasites.
3. What is the precise activation step that initiates the antimalarial activity of artemisinin derivatives?
A) Ferrous (Fe2+) iron derived from heme cleaves the endoperoxide bridge, generating carbon-centered free radicals that alkylate parasite biomolecules
B) Hepatic CYP3A4 oxidizes artemisinin to an active phenolic metabolite that inhibits heme polymerization
C) Acidic pH in the digestive vacuole protonates artemisinin, trapping it as an ion that chelates heme
D) Parasite dihydrofolate reductase reduces artemisinin to its active radical form
E) Artemisinin is hydrolyzed by parasite esterases into quinine-like alkaloids
ANSWER: A
Rationale:
The endoperoxide (peroxide) bridge of artemisinins is cleaved by ferrous (Fe2+) iron supplied by heme released during hemoglobin digestion. This reductive cleavage generates carbon-centered free radicals that alkylate and damage parasite proteins, lipids, and membranes, producing rapid killing. This is the precise activation step.
Option B: Option B is incorrect because activity does not depend on CYP3A4 generating a phenolic metabolite; the parent endoperoxide is activated intraparasitically by heme iron (although dihydroartemisinin is the shared active form, its activation step is still iron-mediated endoperoxide cleavage).
Option C: Option C is incorrect because protonation/ion trapping describes the accumulation of weak-base quinolines such as chloroquine, not artemisinin activation.
Option D: Option D is incorrect because dihydrofolate reductase is an antifolate target and plays no role in artemisinin activation.
Option E: Option E is incorrect because artemisinins are not hydrolyzed into quinine-like alkaloids; they are chemically unrelated endoperoxides.
4. Primaquine's mechanism of action differs fundamentally from that of the blood schizonticides such as chloroquine. Which statement best describes the leading mechanistic explanation for primaquine's activity?
A) It binds free heme and prevents hemozoin formation in the digestive vacuole
B) It inhibits parasite dihydropteroate synthase, blocking folate synthesis
C) Its metabolites generate reactive oxygen species and disrupt parasite mitochondrial function, producing oxidative damage that is effective against liver-stage (hypnozoite and schizont) parasites
D) It alkylates parasite DNA through nitrogen-mustard chemistry
E) It blocks parasite microtubule assembly, arresting mitosis
ANSWER: C
Rationale:
The leading mechanistic account of primaquine activity is that its oxidative metabolites generate reactive oxygen species and interfere with the parasite mitochondrial electron transport chain, producing oxidative damage. This mechanism is effective against liver-stage forms, including hypnozoites and hepatic schizonts, which sets primaquine apart from blood schizonticides such as chloroquine. The same oxidative chemistry explains primaquine's hemolytic toxicity in G6PD-deficient erythrocytes. This is correct.
Option A: Option A is incorrect because it describes chloroquine (heme/hemozoin), not primaquine.
Option B: Option B is incorrect because it describes the sulfonamide antifolates (dihydropteroate synthase), not primaquine.
Option D: Option D is incorrect because primaquine does not act by nitrogen-mustard DNA alkylation.
Option E: Option E is incorrect because microtubule/mitotic-spindle inhibition is not the primaquine mechanism.
5. In the fixed combination atovaquone-proguanil, what is the molecular target of the atovaquone component, and how does proguanil contribute?
A) Atovaquone inhibits dihydrofolate reductase, while proguanil inhibits dihydropteroate synthase, giving sequential folate blockade
B) Atovaquone binds free heme, while proguanil prevents its polymerization to hemozoin
C) Atovaquone cleaves into radicals via heme iron, while proguanil prolongs its half-life
D) Atovaquone blocks the apicoplast ribosome, while proguanil blocks the digestive vacuole transporter
E) Atovaquone inhibits the parasite cytochrome bc1 complex and collapses the mitochondrial membrane potential, and proguanil potentiates this collapse (its parent compound synergizes with atovaquone independent of the cycloguanil antifolate effect)
ANSWER: E
Rationale:
Atovaquone inhibits the parasite mitochondrial cytochrome bc1 complex (complex III), blocking electron transport and collapsing the mitochondrial membrane potential, which halts pyrimidine biosynthesis dependent on the electron-transport-linked enzyme dihydroorotate dehydrogenase. Proguanil itself (the parent compound, distinct from its cycloguanil metabolite) lowers the concentration of atovaquone needed to collapse the membrane potential, producing synergy. This is correct.
Option A: Option A is incorrect because atovaquone is not a dihydrofolate reductase inhibitor; that is cycloguanil/pyrimethamine.
Option B: Option B is incorrect because it describes chloroquine, not atovaquone.
Option C: Option C is incorrect because it describes artemisinin radical chemistry, not atovaquone.
Option D: Option D is incorrect because atovaquone targets cytochrome bc1, not the apicoplast ribosome, and proguanil's synergy is at the mitochondrion, not a vacuolar transporter.
6. Proguanil has antimalarial activity that depends on its biotransformation. Which statement most precisely characterizes this relationship?
A) Proguanil is intrinsically active and requires no metabolism; its parent form inhibits dihydrofolate reductase directly
B) Proguanil is a prodrug whose active metabolite cycloguanil inhibits parasite dihydrofolate reductase, blocking folate-dependent DNA synthesis
C) Proguanil is metabolized to chloroquine, which then inhibits hemozoin formation
D) Proguanil's active metabolite inhibits dihydropteroate synthase, the same enzyme targeted by sulfadoxine
E) Proguanil must be cleaved by heme iron into free radicals before it is active
ANSWER: B
Rationale:
Proguanil is a prodrug. It is biotransformed (chiefly by CYP2C19) to cycloguanil, the active metabolite, which inhibits parasite dihydrofolate reductase and thereby blocks the folate-dependent synthesis of nucleotides required for DNA replication. This antifolate effect is separate from the parent compound's synergy with atovaquone at the mitochondrion. This is precisely correct.
Option A: Option A is incorrect because the antifolate activity resides in the cycloguanil metabolite, not the unmetabolized parent.
Option C: Option C is incorrect because proguanil is not converted to chloroquine and does not act by inhibiting hemozoin formation.
Option D: Option D is incorrect because cycloguanil inhibits dihydrofolate reductase, not dihydropteroate synthase (the latter is the sulfadoxine target).
Option E: Option E is incorrect because proguanil activation is by hepatic metabolism to cycloguanil, not by heme-iron radical cleavage.
7. Which pharmacokinetic profile most accurately characterizes chloroquine and explains both its persistence and its prophylactic dosing schedule?
A) Small volume of distribution with a half-life of a few hours, requiring multiple daily doses
B) Negligible tissue binding with rapid renal elimination, requiring continuous infusion
C) Very large volume of distribution due to extensive tissue binding, with a terminal elimination half-life on the order of weeks to months, allowing once-weekly suppressive prophylaxis and producing prolonged residual levels
D) High first-pass hepatic extraction that renders oral chloroquine inactive
E) Exclusive biliary elimination with a half-life of minutes
ANSWER: C
Rationale:
Chloroquine has an enormous apparent volume of distribution because of extensive binding to tissues, and a terminal elimination half-life measured in weeks to one to two months. This explains its once-weekly suppressive prophylaxis schedule, its prolonged residual presence after the last dose, and the persistence of toxicity if it develops. This is correct.
Option A: Option A is incorrect because chloroquine is long-acting, not short-acting with a multi-dose-per-day schedule.
Option B: Option B is incorrect because chloroquine is heavily tissue-bound, not minimally bound and rapidly cleared.
Option D: Option D is incorrect because oral chloroquine is well absorbed and active, not inactivated by high first-pass extraction.
Option E: Option E is incorrect because chloroquine has a long half-life with substantial renal excretion of unchanged drug and active metabolite, not minutes-long biliary-only elimination.
8. A patient is prescribed artemether-lumefantrine for uncomplicated falciparum malaria. Which administration instruction is essential for the lumefantrine component to be effective?
A) Take each dose with food, ideally containing fat, because lumefantrine absorption is highly dependent on dietary fat and is poor when taken fasting
B) Take each dose on an empty stomach, because food abolishes lumefantrine absorption
C) Take the doses with grapefruit juice to inhibit metabolism and boost levels
D) Crush and dissolve the tablets in an alkaline solution to ensure ionization
E) Avoid all fluids for two hours after each dose to prevent dilution
ANSWER: A
Rationale:
Lumefantrine is a highly lipophilic partner drug whose oral absorption is markedly enhanced by dietary fat and is unreliably low when taken fasting; patients must take artemether-lumefantrine with food, preferably containing some fat, to achieve therapeutic exposure and prevent recrudescence. This is correct.
Option B: Option B is incorrect because it inverts the requirement: food enhances, not abolishes, absorption.
Option C: Option C is incorrect because grapefruit-juice CYP inhibition is not the recommended or safe way to manage lumefantrine exposure.
Option D: Option D is incorrect because crushing into an alkaline solution is not required and ionization manipulation is not how lumefantrine absorption is optimized.
Option E: Option E is incorrect because fluid restriction has no role; co-administration with a fat-containing meal is the key instruction.
9. Which property of mefloquine accounts for its once-weekly prophylactic dosing schedule, and to which structural class does it belong?
A) A half-life of about 6 hours, requiring frequent dosing, in the 8-aminoquinoline class
B) Rapid renal clearance within 24 hours, in the artemisinin class
C) Activation only after hepatic metabolism, in the sulfonamide class
D) A long elimination half-life of roughly 2 to 3 weeks, allowing once-weekly dosing, in the arylaminoalcohol class (structurally related to quinine)
E) Irreversible tissue binding that permits a single lifetime dose, in the 4-aminoquinoline class
ANSWER: D
Rationale:
Mefloquine is an arylaminoalcohol structurally related to quinine, and it has a long elimination half-life of approximately 2 to 3 weeks. That long half-life is precisely what permits once-weekly prophylactic dosing and is also why it is started in advance of travel. This is correct.
Option A: Option A is incorrect on both counts: mefloquine is long-acting, not a 6-hour drug, and it is not an 8-aminoquinoline.
Option B: Option B is incorrect because mefloquine is not rapidly renally cleared and is not an artemisinin.
Option C: Option C is incorrect because mefloquine is intrinsically active and is not a sulfonamide.
Option E: Option E is incorrect because weekly dosing reflects a multi-week half-life, not irreversible binding or single-lifetime dosing, and mefloquine is not a 4-aminoquinoline (that class includes chloroquine).
10. How does tafenoquine differ from primaquine in the radical cure of Plasmodium vivax, and what shared precaution applies?
A) Tafenoquine is a short-acting blood schizonticide given for 14 days; no pre-treatment testing is needed
B) Tafenoquine is a 4-aminoquinoline that replaces chloroquine for blood-stage treatment; it requires retinal screening
C) Tafenoquine is a long-acting 8-aminoquinoline given as a single dose for radical cure, in contrast to the multiday primaquine course, and both require G6PD testing before use because of oxidative hemolysis risk
D) Tafenoquine is an artemisinin derivative given by injection; both it and primaquine require QT monitoring
E) Tafenoquine is a sulfonamide antifolate; both agents require sulfa allergy screening
ANSWER: C
Rationale:
Tafenoquine is a long-acting 8-aminoquinoline that achieves radical cure of vivax with a single dose, whereas primaquine requires a multiday (typically 14-day) course. Because both are 8-aminoquinolines that generate oxidative stress, both require quantitative G6PD testing before use, and tafenoquine's long half-life makes its hemolysis particularly hazardous and non-reversible in G6PD deficiency. This is correct.
Option A: Option A is incorrect because tafenoquine is a long-acting anti-relapse 8-aminoquinoline, not a short-acting blood schizonticide, and pre-treatment G6PD testing is required.
Option B: Option B is incorrect because tafenoquine is an 8-aminoquinoline, not a 4-aminoquinoline, and the key precaution is G6PD testing, not retinal screening.
Option D: Option D is incorrect because tafenoquine is not an injectable artemisinin and the shared precaution is G6PD testing, not QT monitoring.
Option E: Option E is incorrect because tafenoquine is not a sulfonamide and the shared precaution is G6PD testing, not sulfa-allergy screening.
11. For severe Plasmodium falciparum malaria, what is the first-line parenteral agent and the evidence-based reason it is preferred over the alternative?
A) Intravenous quinine, because it produces faster parasite clearance and lower mortality than artesunate
B) Intravenous artesunate, because large randomized trials demonstrated faster parasite clearance and a significant mortality reduction compared with intravenous quinine
C) Intravenous chloroquine, because resistance does not affect parenteral administration
D) Intravenous primaquine, because it provides both blood-stage and liver-stage coverage in severe disease
E) Intravenous doxycycline monotherapy, because it is the fastest-acting parenteral schizonticide
ANSWER: B
Rationale:
Intravenous artesunate is the first-line treatment for severe malaria. Large randomized controlled trials showed faster parasite clearance and a significant reduction in mortality with artesunate compared with intravenous quinine in both adults and children, which is why artesunate replaced quinine and quinidine as the preferred parenteral agent. This is correct.
Option A: Option A is incorrect because it inverts the evidence: quinine is inferior to artesunate for survival in severe malaria.
Option C: Option C is incorrect because chloroquine is not used for severe falciparum disease, particularly given resistance.
Option D: Option D is incorrect because primaquine is an anti-relapse/transmission-blocking 8-aminoquinoline, not a parenteral treatment for severe acute malaria.
Option E: Option E is incorrect because doxycycline is a slow-acting companion agent, not a rapid parenteral schizonticide suitable as monotherapy for severe disease.
12. A patient receiving intravenous quinine for malaria develops hypoglycemia. What is the principal mechanism, and what coexisting factor worsens it?
A) Quinine inhibits hepatic gluconeogenesis directly, and dexamethasone co-therapy aggravates it
B) Quinine causes osmotic glucose loss in urine, and dehydration aggravates it
C) Quinine blocks intestinal glucose absorption, and fasting aggravates it
D) Quinine induces insulin resistance, and obesity aggravates it
E) Quinine stimulates pancreatic beta-cell insulin secretion, producing hyperinsulinemic hypoglycemia, and this is compounded by the high glucose consumption of Plasmodium falciparum infection
ANSWER: E
Rationale:
Quinine is a potent stimulus to pancreatic beta-cell insulin secretion, producing hyperinsulinemic hypoglycemia; this is an important and sometimes overlooked complication during treatment of severe malaria, and it is compounded by the increased glucose utilization of a high falciparum parasite burden (and by the metabolic demands of the illness). This is correct on both elements.
Option A: Option A is incorrect because the mechanism is insulin secretion, not direct inhibition of gluconeogenesis, and dexamethasone (which raises glucose) would not aggravate hypoglycemia.
Option B: Option B is incorrect because quinine hypoglycemia is not due to urinary glucose loss.
Option C: Option C is incorrect because it is not caused by blocking intestinal glucose absorption.
Option D: Option D is incorrect because quinine causes hyperinsulinemia, not insulin resistance.
13. Which molecular change is the primary determinant of chloroquine resistance in Plasmodium falciparum, and what is the role of the secondary gene most often implicated?
A) The K76T mutation in the pfcrt-encoded digestive vacuole transporter is the primary determinant, exporting chloroquine from the vacuole; mutations in pfmdr1 act as a secondary modulator of the degree of resistance
B) Amplification of pfkelch13 is the primary determinant; pfcrt plays no role
C) A mutation in dihydrofolate reductase is the primary determinant; pfdhps modulates it
D) Loss of the apicoplast genome is the primary determinant; pfmdr1 restores it
E) Overexpression of cytochrome bc1 is the primary determinant; pfcrt suppresses it
ANSWER: A
Rationale:
The lysine-to-threonine substitution at codon 76 (K76T) in the pfcrt gene, which encodes the Plasmodium falciparum chloroquine resistance transporter in the digestive vacuole membrane, is the primary determinant of chloroquine resistance; the mutant transporter exports chloroquine from the vacuole, lowering drug concentration at its site of action. Mutations in pfmdr1 (the P-glycoprotein homolog 1 gene) act as secondary modulators that adjust the level of resistance. This is correct.
Option B: Option B is incorrect because pfkelch13 governs artemisinin partial resistance, not chloroquine resistance, and pfcrt is central to chloroquine resistance.
Option C: Option C is incorrect because dihydrofolate reductase and pfdhps mutations govern antifolate (sulfadoxine-pyrimethamine) resistance, not chloroquine.
Option D: Option D is incorrect because chloroquine resistance is not due to loss of the apicoplast genome.
Option E: Option E is incorrect because cytochrome bc1 is the atovaquone target and is not the basis of chloroquine resistance.
14. Which molecular marker is associated with artemisinin partial resistance, and how does that resistance manifest clinically?
A) The pfcrt K76T mutation, manifesting as complete failure of all artemisinin killing within hours
B) The pfdhps A437G mutation, manifesting as immediate recrudescence after a single dose
C) Mutations in the propeller domain of pfkelch13 (for example C580Y), manifesting as delayed parasite clearance (a prolonged parasite clearance half-life) rather than outright immediate failure
D) Amplification of pfmdr1 alone, manifesting as resistance only to primaquine
E) Loss-of-function of dihydroorotate dehydrogenase, manifesting as resistance to chloroquine
ANSWER: C
Rationale:
Artemisinin partial resistance is marked by mutations in the propeller domain of the pfkelch13 gene, with C580Y the most prominent. Clinically it manifests as delayed parasite clearance — a prolonged parasite clearance half-life on therapy — rather than abrupt, complete treatment failure; outright clinical failure typically emerges only when partner-drug resistance also develops. This is correct.
Option A: Option A is incorrect because K76T is the chloroquine-resistance marker and artemisinin partial resistance is delayed clearance, not instantaneous total failure.
Option B: Option B is incorrect because pfdhps mutations govern sulfadoxine resistance, not artemisinin.
Option D: Option D is incorrect because pfmdr1 amplification is not the defining artemisinin marker and does not selectively confer primaquine resistance.
Option E: Option E is incorrect because dihydroorotate dehydrogenase relates to the pyrimidine pathway downstream of atovaquone's target and is not the basis of chloroquine resistance.
15. Sulfadoxine-pyrimethamine acts on the parasite folate pathway. Which statement correctly identifies its dual enzymatic targets and a current clinical use?
A) Sulfadoxine inhibits dihydrofolate reductase and pyrimethamine inhibits dihydropteroate synthase; used as first-line treatment for severe malaria
B) Both components inhibit cytochrome bc1; used only for chloroquine-resistant prophylaxis
C) Both components inhibit hemozoin formation; used as the preferred radical-cure regimen
D) Sulfadoxine inhibits dihydropteroate synthase and pyrimethamine inhibits dihydrofolate reductase, producing sequential blockade of folate synthesis; it retains a role in intermittent preventive treatment in pregnancy
E) Sulfadoxine cleaves the artemisinin endoperoxide and pyrimethamine chelates iron; used for transmission blocking
ANSWER: D
Rationale:
Sulfadoxine-pyrimethamine produces sequential blockade of the folate biosynthesis pathway: sulfadoxine inhibits dihydropteroate synthase (DHPS) and pyrimethamine inhibits dihydrofolate reductase (DHFR), depleting the reduced folates the parasite needs for nucleotide synthesis. Although resistance has eroded its use as a treatment, it retains a role in intermittent preventive treatment in pregnancy (and in seasonal chemoprevention regimens). This is correct.
Option A: Option A is incorrect because it inverts the enzyme assignments and wrongly lists it as first-line treatment for severe malaria.
Option B: Option B is incorrect because neither component targets cytochrome bc1.
Option C: Option C is incorrect because the agents act on the folate pathway, not hemozoin, and they are not a radical-cure regimen.
Option E: Option E is incorrect because neither component cleaves the artemisinin endoperoxide or works by iron chelation.
16. Why are doxycycline and clindamycin paired with quinine rather than used alone for acute malaria, and what is their mechanism?
A) They are rapid-acting schizonticides that cure malaria within hours, so quinine is added only for taste
B) They inhibit hemozoin formation faster than chloroquine, making quinine redundant
C) They are 8-aminoquinolines that eradicate hypnozoites, so they replace primaquine
D) They cleave the artemisinin endoperoxide, so they substitute for artemisinin in an ACT
E) They are slow-acting blood schizonticides that act on the parasite apicoplast (a plastid organelle) by inhibiting its ribosomal protein synthesis, so they are paired with rapid-acting quinine to provide companion coverage and reduce resistance selection over a 7-day course
ANSWER: E
Rationale:
Doxycycline and clindamycin act on the parasite apicoplast (a relict plastid organelle essential to the parasite) by inhibiting apicoplast ribosomal protein synthesis. Their antimalarial killing is delayed (slow-acting) because the apicoplast defect manifests over the subsequent replication cycle, so they cannot rapidly control an acute infection alone; they are paired with rapid-acting quinine for a 7-day course to provide companion coverage and reduce resistance selection. This is correct.
Option A: Option A is incorrect because these antibiotics are slow-acting, not rapid curatives, and quinine is the rapid component, not a flavoring.
Option B: Option B is incorrect because they do not act by inhibiting hemozoin formation and do not make quinine redundant.
Option C: Option C is incorrect because they are antibiotics, not 8-aminoquinolines, and have no hypnozoite (radical-cure) activity.
Option D: Option D is incorrect because they do not cleave the artemisinin endoperoxide and are not artemisinin substitutes.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.